Potential for vitamin D receptor agonists in the treatment of cardiovascular disease
Author:
- 28 August 2009
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 158 (2) , 395-412
Abstract
Vitamin D3 is made in the skin and modified in the liver and kidney to form the active metabolite, 1,25‐dihydroxyvitamin D3 (calcitriol). Calcitriol binds to a nuclear receptor, the vitamin D receptor (VDR), and activates VDR to recruit cofactors to form a transcriptional complex that binds to vitamin D response elements in the promoter region of target genes. During the past three decades the field has focused mainly on the role of VDR in the regulation of parathyroid hormone, intestinal calcium/phosphate absorption and bone metabolism; several VDR agonists (VDRAs) have been developed for the treatment of osteoporosis, psoriasis and hyperparathyroidism secondary to chronic kidney disease (CKD). Emerging evidence suggests that VDR plays important roles in modulating cardiovascular, immunological, metabolic and other functions. For example, data from epidemiological, preclinical and clinical studies have shown that vitamin D and/or 25(OH)D deficiency is associated with increased risk for cardiovascular disease (CVD). However, VDRA therapy seems more effective than native vitamin D supplementation in modulating CVD risk factors. In CKD, where decreasing VDR activation persists over the course of the disease and a majority of the patients die of CVD, VDRA therapy was found to provide a survival benefit in both pre‐dialysis and dialysis CKD patients. Although VDR plays an important role in regulating cardiovascular function and VDRAs may be potentially useful for treating CVD, at present no VDRA is approved for CVD, and also no serum markers, beside parathyroid hormone in CKD, exist to indicate the efficacy of VDRA in CVD.Keywords
This publication has 164 references indexed in Scilit:
- Variability and Risk Factors for Kidney Disease Progression and Death Following Attainment of Stage 4 CKD in a Referred CohortAmerican Journal of Kidney Diseases, 2008
- 25-Hydroxyvitamin D Levels and the Risk of Mortality in the General PopulationArchives of internal medicine (1960), 2008
- Oral Calcitriol for the Treatment of Persistent Proteinuria in Immunoglobulin A Nephropathy: An Uncontrolled TrialAmerican Journal of Kidney Diseases, 2008
- Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animalsProceedings of the National Academy of Sciences, 2007
- Vitamin D Supplementation and Total MortalityA Meta-analysis of Randomized Controlled TrialsArchives of internal medicine (1960), 2007
- Prevalence of Cardiovascular Risk Factors and the Serum Levels of 25-Hydroxyvitamin D in the United StatesArchives of internal medicine (1960), 2007
- Characterization of heart size and blood pressure in the vitamin D receptor knockout mouseThe Journal of Steroid Biochemistry and Molecular Biology, 2007
- Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patientsKidney International, 2006
- Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal studyKidney International, 2006
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004